CREON Dosing

For appropriate weight-based dosing, perform the CREON Dosing Check

*The CFF Guidelines also provide a dietary fat-based maximum lipase dose of less than 4,000 lipase units per g of fat ingested per day

CREON® is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.1
CREON should be administered in a manner consistent with the recommendations of the Cystic Fibrosis Foundation (CFF) Consensus Conferences.

  • CREON should always be taken with food. CREON should not be crushed or chewed.
  • Usually, half of the prescribed CREON dose for an individualized full meal should be given with each snack.
  • Fibrosing colonopathy has been reported in patients with cystic fibrosis taking high-dose pancreatic enzyme replacement therapy.
INFANTS (up to 12 months)

3,000 lipase units/120 mL of formula or per breast-feeding

Additional Infant Dosing Information

CFF Consensus Conference Guidelines

CHILDREN (> 12 months to < 4 years)

Per meal

  • Lipase units per kg of body weight

1,000 to 2,500

Per day (max dose)

  • Lipase units per kg of body weight
  • Lipase units per g of fat ingested

≤10,000

<4,000
INDIVIDUALS (≥ 4 years)

Per meal

  • Lipase units per kg of body weight

500 to 2,500

Per day (max dose)

  • Lipase units per kg of body weight
  • Lipase units per g of fat ingested

≤10,000

<4,000

IMPORTANT SAFETY INFORMATION

  • Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
  • To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
  • Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
  • There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
  • Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
  • Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
  • CREON is not interchangeable with any other pancrelipase product.

INDICATIONS

CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Reference:
  1. CREON [package insert].

OTHER TOPICS


CREON Dosing

See CREON dosing guidelines.


Patient Support Program

CFCareForward offers nutritional, financial, and educational resources.


CREON MOA

See how CREON works.